Brontictuzumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Brontictuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetNotch 1
Clinical data
SynonymsOMP-52M51
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6392H9862N1980O1710S50
Molar mass143.9 kDa

Brontictuzumab (OMP-52M51) (INN) is a humanized monoclonal antibody designed for the treatment of cancer.[1][2]

This drug was developed by OncoMed Pharmaceuticals.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Brontictuzumab, American Medical Association.
  2. ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).